LJI research shows that a “slow delivery, escalating dose” vaccination strategy can prompt B cells to spend months mutating and evolving their pathogen-fighting antibodies.
The David Geffen School of Medicine at UCLA has been awarded a $13.6 million grant from the Centers for Disease Control and Prevention to continue to study the effectiveness of COVID-19 vaccines and the long-term impact of infection among U.S. health care workers. The new yearlong grant project follows the 2020–21 Preventing Emerging Infections Through Vaccine Effectiveness Testing study, or PREVENT I, which was among the first to demonstrate the real-world benefit of mRNA vaccines in preventing symptomatic infection following their authorization by the Food and Drug Administration.
People with systemic lupus erythematosus, or SLE, who received a “booster” dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent “breakthrough” COVID-19 infection, a new study shows.
Most patients in the study mounted immune responses after a booster dose, and no patient with antibody responses died from COVID-19.
Joanna Drowos, D.O., M.P.H., M.B.A., FAU Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 boosters and vaccines for children ages 5 to 11.